Medivation (MDVN) Tops Q2 EPS by 13c

Medivation (NASDAQ: MDVN) reported Q2 EPS of $0.58, $0.13 better than the analyst estimate of $0.45. Revenue for the quarter came in at $175.7 million versus the consensus estimate of $159.42 million.

"XTANDI's performance, in both the U.S. and outside the U.S., demonstrates continued traction toward becoming a foundation of therapy for the treatment of metastatic castration-resistant prostate cancer," said David Hung, M.D., president and chief executive officer of Medivation. "Medivation will continue to pursue innovative programs that have the potential to make a meaningful impact in the quality of life of patients with serious disease."

For earnings history and earnings-related data on Medivation (MDVN) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c
• Cummins wins battery storage contract for U.S. data center project